Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems.
A 10-year double-blind prospective study was undertaken to evaluate the effects of estrogen replacement therapy (ERT). The sample population consisted of 84 pairs of randomly chosen postmenopausal in-patients, matched for age and diagnosis. The treatment group received high-dose conjugated estrogens, cyclically with progesterone. The controls recieved placebos. Results revealed no statistically significant difference in that incidence of thrombophlebitis, myocardial infarction (MI), or uterine cancer. There was a lower incidence of breast cancer in the treated group. Estrogen-treated patients showed a higher incidence of cholelithiasis. Those in the treated group who began the study with elevated beta/alpha lipoprotein ratios showed a reduction in that ratio over the course of the study, while the controls either maintained or increased their ratios. The low number of cases precludes drawing any real significance from the data on diseases of low frequency. The study excludes only a high incidence of complications from estrogens.
D000328:Adult; D001943:Breast Neoplasms / Q000453:epidemiology; D002769:Cholelithiasis / Q000139:chemically induced; D004311:Double-Blind Method; D004966:Estrogens, Conjugated (USP) / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced*; D009519:New York City; D011374:Progesterone / Q000009:adverse effects; D011446:Prospective Studies; D013924:Thrombophlebitis / Q000139:chemically induced*; D014594:Uterine Neoplasms / Q000139:chemically induced*
D004966:Estrogens, Conjugated (USP); D008074:Lipoproteins; D011374:Progesterone